Aaron Peterson
Psychiatry · Houston, TXNPI 1457545303
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $621,685 of the $699,752 with a category attached, or 88.8%. AbbVie accounts for 94.1% of it on its own, with 39 other manufacturers making up the rest. 2025 is the largest year on record at $154,850, 4.2 times the $37,071 reported in 2019. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,912 payments — averaging $365.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$658K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21K
- Vanda Pharmaceuticals Inc.$6K
- Axsome Therapeutics, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Lundbeck LLC$1K
- plus $10K from 34 others
What the payments were for
- Consulting fees$7,0001%
- Speaking & faculty fees$621,68589%
- Travel & lodging$41,2876%
- Food & beverage$29,5574%
- Education$2220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$699,752 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 12 | $28,545 |
| Dyanavel XrAmphetamine | 15 | $8,230 |
| Vilazodone Hcl | 35 | $4,806 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $2,658 |
| Aripiprazole | 16 | $1,747 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 22 | $1,683 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 44 | $1,647 |
| Dextroamphetamine Sulfate | 21 | $1,592 |
| Methylphenidate Hcl | 35 | $1,361 |
| Quetiapine Fumarate | 70 | $1,360 |
| Duloxetine Hcl | 65 | $1,353 |
| Trazodone Hcl | 95 | $1,221 |
| Lamotrigine | 113 | $1,173 |
| Bupropion XlBupropion Hcl | 50 | $928 |
| Sertraline Hcl | 51 | $573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $5,717 | $28,54512 claims |
| Tris Pharma IncDyanavel Xr | $936 | $8,23015 claims |
| Almatica Pharma LLCSertraline Hcl | $81 | $57351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
- Prashant GajwaniHouston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.